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Abstract In this study, we investigated the intestinal absorption
of luteolin and luteolin 7-O-L-glucoside in rats by HPLC. The
absorption analysis using rat everted small intestine demon-
strated that luteolin was converted to glucuronides during passing
through the intestinal mucosa and that luteolin 7-O-L-glucoside
was absorbed after hydrolysis to luteolin. Free luteolin, its
conjugates and methylated conjugates were present in rat plasma
after dosing. This suggests that some luteolin can escape the
intestinal conjugation and the hepatic sulfation/methylation. LC/
MS analysis showed that the main conjugate which circulates in
the blood was a monoglucuronide of the unchanged aglycone.
Luteolin in propyleneglycol was absorbed more rapidly than that
in 0.5% carboxymethyl cellulose. The plasma concentration of
luteolin and its conjugates reached the highest level 15 min and
30 min after dosing with luteolin in propyleneglycol, respectively.
HPLC analysis also allowed us to demonstrate the presence of
free luteolin and its monoglucuronide in human serum after
ingestion of luteolin.
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1. Introduction
Flavonoids occur naturally in the plant kingdom. They are
common dietary components of vegetables, fruits, wine and
tea. Epidemiological studies showed that the dietary intake of
£avonoids was inversely associated with the mortality from
coronary heart disease [1] and the incidence of stroke [2].
These correlations may implicate in part the inhibition of
low density lipoprotein oxidation and platelet aggregation
[3,4]. Flavonoids have been reported to exert an antioxidant
activity due to their ability to scavenge free radicals or to
chelate metal ions [5,6].
Luteolin, the £avone subclass of £avonoids, usually occurs
as glycosylated forms in celery, green pepper, perilla leaf and
camomile tea, etc., and as an aglycone in perilla seeds. It has
been reported to be non-mutagenic [7], antimutagenic [8],
antitumorigenic [9] and anti-in£ammatory-allergic [10] and
has been recognized as a hydroxyl radical scavenger [5] and
an inhibitor of protein kinase C [11]. Our previous study
demonstrated that preadministration of luteolin reduced the
frequency of micronucleated reticulocytes (MNRETs) in
mouse peripheral blood cells [12], suppressed Q-ray-induced
lipid peroxidation in mouse bone marrow and spleen [13]
and also inhibited the doxorubicin-induced elevation of the
lipid peroxide level in mouse heart and bone marrow [14].
It is very important to evaluate the bioavailability of £avo-
noids in order to clarify whether the absorbed £avonoids
function as antioxidants in vivo. Recently, Hollman et al.
reported that humans absorb appreciable amounts of querce-
tin and the absorption is enhanced by conjugation with glu-
cose [15]. Manach et al. demonstrated that dietary rutin was
recovered in substantial concentration in rat plasma as two
conjugated metabolites and was absorbed more slowly than
quercetin [16]. Rutin must be hydrolyzed by the intestinal
micro£ora. Liu et al. characterized the metabolites of luteolin
in rat urine and bile by GC/MS analysis [17]. However, there
is little information concerning pharmacokinetics and identi-
¢cation of metabolites in the blood plasma after ingestion of
£avonoids. The mechanism of intestinal absorption and the
pharmacokinetics of luteolin and its glycosides have not been
well elucidated so far.
In this study, we investigated how luteolin and luteolin 7-O-
L-glucoside are absorbed from the digestive tract using rat
everted intestine, determined the plasma levels of luteolin
and its conjugates by HPLC and LC/MS analyses, and com-
pared the metabolites in rat plasma with those in human
plasma.
2. Materials and methods
2.1. Chemicals
Luteolin and chrysoeryol were isolated from perilla seed and puri-
¢ed by HPLC at the Oryza Oil and Fat Chemical Co. (Ichinomiya,
Japan). Luteolin 7-O-L-glucoside and diosmetin were obtained from
Extrasynthese (Genay, France). L-Glucuronidase/sulfatase and L-glu-
curonidase were purchased from Sigma (St. Louis, MO, USA) and
Wako Pure Chem. Ind. (Osaka, Japan), respectively.
2.2. Animals and diets
Male SD rats (7^9 weeks old, SLC, Hamamatsu, Japan), weighing
180^200 g, were housed in an air-conditioned room, fed CE-2 com-
mercial food pellets (Crea Japan, Tokyo, Japan) ad libitum at ¢rst,
and this diet was changed to a synthetic basic diet which consists of
38% corn starch, 25% casein, 10% K starch, 8% cellulose powder, 6%
minerals, 5% sugar, 2% vitamins and 6% lard (Oriental Yeast, Tokyo,
Japan) one week before the experiments. Three to ¢ve rats were as-
signed to each experimental group. Animals were maintained and
handled according to Guidelines for the Regulation of Animal Exper-
imentation Committee of the University of Shizuoka.
2.3. Sample preparation of blood
Rats fasted overnight were anesthetized with ethyl ether at di¡erent
times after administration of luteolin or luteolin 7-O-L-glucoside (50
Wmol/kg in 0.5% carboxymethyl cellulose sodium, CMC-Na or pro-
pyleneglycol) by gastric intubation, and blood was withdrawn from
the abdominal aorta into heparinized tubes. Two human volunteers
(female: 55 kg, male: 75 kg) gave informed consent before the experi-
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ment. They ingested 50 mg of luteolin suspended in starch solution
and their venous blood was collected in vacuum containers by a
medical doctor 3 h after ingestion.
2.4. Absorption experiment with everted intestine
The intestinal absorption of luteolin and luteolin 7-O-L-glucoside
from the mucosa to the serosal side was studied as previously de-
scribed [18] with some modi¢cations. Brie£y, rats fasted overnight
were anesthetized with pentobarbital, and six consecutive segments
of 2.5 cm each were dissected from the middle part of the upper
half (jejunum) of the small intestine and rinsed with Ringer’s solution
which contained 140 mM NaCl, 10 mM KHCO3, 0.4 mM KH2PO4,
2.4 mM K2HPO4, 1.2 mM CaCl2W2H2O, 1.2 mM MgCl2W6H2O, and
1 mM glucose (pH 7.4). They were everted and ¢xed over a fenes-
trated conical polypropylene tube attached with a Tygon tubing.
These sacs were placed in 5 ml of Ringer’s solution containing
5 mM sodium cholate, 1.9% Tween 20 and 1 mM luteolin or luteolin
7-O-L-glucoside, and the serosal side was ¢lled with 0.3 ml of Ringer’s
solution. They were incubated bubbling with 95% O2/5% CO2 at
37‡C. The medium of the serosal side was substituted with fresh Ring-
er’s solution 15 min after the start of incubation.
2.5. HPLC analysis
HPLC analysis was performed by the method described previously
with some modi¢cation [19]. The plasma (0.5 ml) and the incubation
medium of the serosal side were acidi¢ed with the same volume of
0.01 M oxalic acid.
This solution was applied to a Sep-Pak C18 cartridge. After washing
the cartridge with 0.01 M oxalic acid, methanol/water/0.5 M oxalic
acid (25:73:2, v/v) and distilled water, the methanol eluate was ob-
tained. For samples in Fig. 5, the cartridge was not washed with
methanol/water/0.5 M oxalic acid (25:73:2, v/v/v). The eluate was
evaporated to dryness and the residue was dissolved in 100 Wl of
methanol. After centrifugation for 2 min at 0‡C at 20 000Ug, the
supernatants were analyzed chromatographically by a JASCO
HPLC system (Tokyo, Japan) using a Capcell Pak C18-UG120 col-
umn (150U4.6 mm I.D., Shiseido, Tokyo, Japan) and UV detection
(349 nm). The mobile phase contained the following: Solvent A,
methanol with 0.03% tri£uoroacetic acid; Solvent B: distilled water
with 0.03% tri£uoroacetic acid. The column temperature was main-
tained at 50‡C and the £ow rate was 0.7 ml/min. Quanti¢cation of
luteolin was done by measuring the peak areas based on calibration
plots of the peak area of standard luteolin at various concentrations.
For detection of the conjugates, each sample was acidi¢ed with 1 M
acetate bu¡er (pH 4.5) and was preincubated for 2 min at 37‡C.
Solutions were treated with 5.4U102 units/ml L-glucuronidase and
0.2U102 units/ml sulfatase for 20 min at 37‡C, and then the same
volume of 0.01 M oxalic acid was added. The mixtures were centri-
fuged for 5 min at 8000 rpm. Supernatants were prepared in the same
way as described above.
The recoveries of luteolin from plasma and the incubation medium
of the serosal side were obtained by spiking luteolin at 1 mg/ml into
each sample. Each recovery was 103.8 þ 2.4% (n = 5), 95.3 þ 7.7%
(n = 5), respectively.
2.6. LC-MS analysis
LC-MS (FRIT FAB ionization method, negative mode) analysis
was performed in a JEOL JMS DX-303 mass spectrometer with a
JASCO liquid chromatograph PU-980 apparatus. Matrix solution
(1% glycerol in methanol) was mixed after the UV detector. The
LC conditions were as follows: column, Capcell Pak C18-UG120 col-
umn (150U2.0 mm I.D., Shiseido, Tokyo, Japan); detection, UV 349
nm; £ow rate, 163 Wl/min; mobile phase, the same as in HPLC anal-
ysis except gradient conditions. The analysis was carried out at 40‡C.
3. Results
Fig. 1A,B,C shows the HPLC chromatograms of the stand-
ards (luteolin 7-O-L-glucoside, luteolin) and the constituents
appearing in the serosal side after intestinal absorption of
luteolin or luteolin 7-O-L-glucoside. Two metabolite peaks
(a: 13.1 min; b: 20.0 min) and luteolin peak (c: 22.8 min)
were observed. After treatment with L-glucuronidase/sulfa-
tase, peaks a and b disappeared and peak c increased (Fig.
1B). These results demonstrated that peaks a and b were
glucuro- and/or sulfo-conjugates. After intestinal absorption
of luteolin 7-O-L-glucoside, peaks a, b and d were observed.
Peak d at a retention time of 12.6 min nearly corresponded
with that of standard luteolin 7-O-L-glucoside. Because L-glu-
curonidase/sulfatase was shown to possess L-glucosidase ac-
tivity, L-glucuronidase was used for deconjugation in the case
of luteolin 7-O-L-glucoside. After treatment with this enzyme,
peaks a and b disappeared and the luteolin peak (c) increased
as observed in the case of luteolin (Fig. 1C). These results
suggest that luteolin 7-O-L-glucoside is mainly hydrolyzed to
luteolin and then luteolin is absorbed, and that peaks a and b
are glucuronides.
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Fig. 1. HPLC chromatograms of the constituents appearing in the serosal side before and after L-glucuronidase or L-glucuronidase/sulfatase
treatment. Gradient conditions: A/B = 30/70, 0^5 min; 30/70C65/35, 5^30 min; 65/35, 30^40 min; 65/35C100/0, 40^45 min. Peaks a: 13.1
min; b: 20.0 min; c: 22.8 min (luteolin); d: 12.6 min; luteolin 7-O-L-glucoside: 12.8 min.
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The HPLC elution pro¢les of rat plasma 3 h after admin-
istration of luteolin and luteolin 7-O-L-glucoside (50 Wmol/kg
in 0.5% CMC-Na) by gastric intubation are shown in Fig. 2B
and C. The same two peaks (b, c) were observed as in Fig. 1B
and C, but peak a was not detected. After treatment with L-
glucuronidase/sulfatase, the peaks of luteolin (c) and diosme-
tin/chrysoeryol (e: 26.9 min) increased. Free luteolin, luteolin
conjugates and methylated conjugates were present in rat
plasma. However, luteolin 7-O-L-glucoside was not detected
in rat plasma.
The methanol fraction of the plasma extract from rats ad-
ministered luteolin was analyzed by LC-MS. Fig. 3A,B,C
shows the HPLC chromatogram and mass spectra. Peaks bP
and cP in the HPLC chromatogram corresponded to peaks b
and c in Figs. 1 and 2. The negative FAB-MS of peaks bP and
cP showed molecular ion peaks at m/z 461 and 285[M-H]3
corresponding to a monoglucuronide of luteolin and luteolin,
respectively. These results indicate that free luteolin is present
in rat plasma and that the main conjugate is a monoglucur-
onide of unchanged luteolin.
In each experiment mentioned above, 3^5 rats were used
and the same results were obtained. Therefore, representative
results are shown in Figs. 1^3.
The time courses of the concentration of luteolin and luteo-
lin conjugates in rat plasma after administration of luteolin in
0.5% CMC-Na and propyleneglycol by gastric intubation (50
Wmol/kg) are shown in Fig. 4. The amount of luteolin con-
jugates in rat plasma was obtained by subtracting the amount
of free luteolin from the total amount of luteolin after treat-
ment with L-glucuronidase/sulfatase. The concentration of lu-
teolin and its conjugates in rat plasma increased to the highest
level 15 min (3.08 nmol/ml) and 30 min (14.1 nmol/ml) after
administration of luteolin in propyleneglycol and decreased
gradually. The intestinal absorption was faster and the plasma
concentration of both luteolin and its conjugates was three
times higher in rats administered luteolin in propyleneglycol
than in those administered luteolin in 0.5% CMC-Na.
As shown in Fig. 5, peaks bQ and cQ, of which the retention
time corresponded to those of peaks b (luteolin monoglucur-
onide) and c (luteolin) in Figs. 1 and 2, were detected in
human serum as well as in rat plasma.
4. Discussion
Recently, the bioavailability, pharmacokinetics and metab-
olism of £avonoids have been focused on in order to evaluate
their important role in the chemoprevention of diseases such
as cancer, heart disease and diabetes, etc. Flavonoids usually
occur in dietary plants in the glycosylated form. Hollman et
al. have reported that quercetin glycosides from onion were
absorbed more e⁄ciently than the aglycone form in ileostomy
patients [15]. Paganga and Rice-Evans have shown evidence
for the absorption of £avonoids and their presence in human
plasma in the glycosylated form [20]. Whether the glycosides
can be absorbed or not and how £avonoids pass through the
intestinal mucosa, however, has not been elucidated.
In this study, the experiment with rat everted small intestine
demonstrated that luteolin 7-O-L-glucoside was hardly ab-
sorbed by itself and luteolin glucuronides were detected after
intestinal absorption. Further, luteolin 7-O-L-glucoside was
not detected in rat plasma after administration. It has been
reported that the intestinal microbacteria can hydrolyze gluco-
sides of £avonoids and produce aglycones [21]. Therefore, we
suggested that luteolin 7-O-L-glucoside may be ¢rst hydro-
lyzed to luteolin by the microbacteria which were present on
the surface of the intestinal mucosa. However, we have pre-
viously reported that KG-Rutin (4G-K-D-glucopyranosylrutin),
which is a water-soluble £avonoid, was absorbed into the
circulation very rapidly and the metabolite was present in
the glycosylated form in mouse plasma [19]. It may depend
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Fig. 2. HPLC chromatograms of plasma extracts from luteolin or luteolin 7-O-L-glucoside administered rats before and after L-glucuronidase
or L-glucuronidase/sulfatase treatment. Gradient conditions and peaks b and c: see Fig. 1. Peak e: 26.9 min (diosmetin and chrysoeryol).
K. Shimoi et al./FEBS Letters 438 (1998) 220^224222
on the type of glycosylated forms whether glycosides can be
absorbed or not. Water-soluble £avonoids may be absorbed
without hydrolysis by intestinal microbacteria.
On the other hand, we showed that the plasma of rats
administered luteolin orally contained free luteolin (unmodi-
¢ed form), glucuronide or sulfate-conjugates of unchanged
luteolin and o-methyl luteolin (diosmetin or chrysoeryol). A
number of previous studies have reported that no free form of
quercetin or diosmetin was detected in rat plasma [22,23].
However, free luteolin was present in rat plasma. Some luteo-
lin could escape the intestinal conjugation and hepatic sulfa-
tion/methylation. The experiment with rat everted small intes-
tine also showed that absorbed luteolin was converted to
glucuronides passing through the intestinal mucosa. Though
the liver is generally considered to have the capacity to con-
jugate £avonoids, the glucuronidation occurs rapidly by
UDP-glucuronosyltransferase in the intestinal mucosa. Fur-
ther we found that luteolin was absorbed more e⁄ciently
from the duodeno-jejunum than the ileum (data not shown).
Pharmacokinetic pro¢les of free luteolin and luteolin con-
jugates in rat plasma are shown in Fig. 4. When rats were
given luteolin in propyleneglycol (50 Wmol/kg) orally, the total
luteolin concentration in rat plasma 30 min after dosing was
15.5 þ 3.8 nmol/ml. Diosmetin was shown to circulate in the
blood in the glucuronide form, and its plasma concentration
at a high level was V10 Wg/ml (V33 nmol/ml) after oral
administration (100 mg/kg) [23]. King et al. have examined
the pharmacokinetics of the soy iso£avone genistein following
a single oral dose of genistein (20 mg/kg) [24]. After treatment
with L-glucuronidase, the plasma concentration of genistein at
2 h after dosing was 11.0 þ 2.3 nmol/ml, which was similar to
our results. On the other hand, the excretory recovery for 24 h
as unmodi¢ed luteolin from the urine was about 4%.
LC/MS analysis showed that the main metabolite in plasma
was a monoglucuronide. Luteolin possesses four hydroxyl
groups at the 3P-, 4P-, 5-, and 7-positions which are available
for glucuronidation. It is unclear which position of luteolin is
a glucuronidation site at the present time. The biological ac-
tivity of luteolin is considered to be associated in part with its
antioxidant potential. The presence of hydroxyl groups is very
important for antioxidant activity. It was suggested that the
cOH scavenging activity is directly related to the number of
hydroxyl groups substituted on ring B, especially at the 3P-
position [5]. Cao et al. have reported that dihydroxyl groups
at the 3P- and 4P-positions play an important role in antiox-
idant reaction. Antioxidant activity decreases with methyla-
tion of the hydroxyl group [25]. Between the hydroxyl group
at the 5-position and the neighboring ketone at the 4-position,
or the ortho-dihydroxyl groups at the 3P- and 4P-positions,
chelating complexes with metal ions are formed. Therefore,
luteolin monoglucuronide possesses chelating ability. The
antioxidant activity of luteolin monoglucuronide might be
lower than that of luteolin. However, it does not lose antiox-
idant potential completely.
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Fig. 4. Concentration of luteolin and its conjugates in rat plasma
after oral administration of luteolin. Luteolin: 50 Wmol/kg (0.5%
CMC-Na and propyleneglycol); luteolin conjugates: plasma samples
were treated with L-glucuronidase/sulfatase. Each value represents
the mean þ S.E. (n = 3).
Fig. 3. HPLC chromatogram and mass spectra of plasma extracts
from luteolin administered rats and standard luteolin. Gradient con-
ditions: A/B = 30/70C65/35, 0^26 min; 65/35C100/0, 26^36 min;
100/0C30/70, 42^60 min. Peaks bP : 18.1 min; cP : 20.9 min (luteo-
lin).
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It is noteworthy that free luteolin and its monoglucuronide
are present in human serum after dosing. According to Man-
ach et al., the high plasma concentration of quercetin metab-
olites was maintained with a regular supply of quercetin in the
diet [16]. Therefore, it is suggested that maintenance of the
£avonoid level in the blood might improve the antioxidant
status in vivo. On the other hand, the pharmacological activ-
ity of glucuronides such as morphine glucuronide was shown
recently [26]. To clarify that luteolin monoglucuronides dem-
onstrate pharmacological activity, further investigations are
required.
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Fig. 5. HPLC chromatograms of extracts from rat plasma and hu-
man serum 3 h after oral administration of luteolin. Luteolin: rats
(50 Wmol/kg in 0.5% CMC-Na); humans (A: male; B: female; 50
mg in starch solution). Gradient conditions: A/B = 5/95, 0^5 min; 5/
95C30/70, 5^30 min; 30/70C40/60, 30^70 min; 40/60C100/0, 70^
80 min. Peaks bQ : 54.2 min (luteolin monoglucuronide); cQ : 61.5
min (luteolin). (+), (3) : with and without L-glucuronidase/sulfatase.
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